ÌÇÐÄÆƽâ°æ

Generics and biosimilars in the U.S.

Statistics report about generics and biosimilars in the U.S.

This report provides information about the generics and biosimilars market in the United States and puts it into global context. It includes valuable information about the market, the industry and its companies, the economic impact, and much more.

Download your Report

  We value your privacy and will never rent or sell your email address.

Privacy

Table of contents

Global Overview & Context

6
  • Premium Statistic Pharmaceutical market size worldwide 2001-2029
  • Basic Statistic Generic drugs market size worldwide 2023-2033
  • Premium Statistic Revenues of leading global generics manufacturers 2024
  • Premium Statistic Global market forecast of biosimilars 2023-2033
  • Premium Statistic Global market share of biosimilars by region 2023
  • Premium Statistic Patent expiration risk for total worldwide global Rx drug revenue 2018-2032

Competitive Landscape

5
  • Premium Statistic Generic drugs revenue top corporations in the U.S. 2023
  • Premium Statistic Generics market share of top corporations in the U.S. 2023
  • Premium Statistic Teva Pharmaceutical Industries' generic revenues by region 2022-2025
  • Premium Statistic Viatris' net sales 2022-2025, by market
  • Premium Statistic Sandoz net sales in the U.S. 2022-2025

Market Penetration & Entry Pipeline

5
  • Premium Statistic Branded vs. generic U.S. drug prescriptions dispensed 2020-2023
  • Premium Statistic Number of ANDAs received in U.S. 2009-2023
  • Premium Statistic Top pharma products by prescriptions U.S. 2023
  • Basic Statistic Projected small molecule sales at risk due to patent expiry in the U.S. 2019-2028
  • Premium Statistic Sales share at risk of pharmaceuticals due to patent expiries U.S. 2022

Biosimilar Market Acceleration

6
  • Basic Statistic Number of biosimilars approved by FDA 2015-2025
  • Basic Statistic New U.S. biosimilar launches of top products 2024-2029
  • Premium Statistic Share of adalimumab sales Humira vs. biosimilars U.S. 2026
  • Premium Statistic Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2024
  • Premium Statistic Share of insulin glargine sales Lantus vs. biosimilar US 2015-2025
  • Premium Statistic Adalimumab wholesale acquisition cost in the U.S. 2024

Pricing & Payer Economics

6
  • Premium Statistic Savings through generic drug usage in the U.S. 2008-2024
  • Premium Statistic Total savings of top generic drugs in U.S. 2015-2024
  • Premium Statistic Saving of U.S. costs through generic pharmaceuticals by condition 2024
  • Premium Statistic Savings through generic drug usage in the U.S., by payer 2024
  • Premium Statistic Savings through generic drug usage in the U.S., by age group 2024
  • Premium Statistic Price reduction of major Medicare expenditure drugs U.S. 2026
Report this content
FURTHER REPORTS

Recommended and recent reports

Recommended statistics

You may also be interested in...
We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch